stoxline Quote Chart Rank Option Currency Glossary
  
Bruker Corporation (BRKR)
93.94  0.08 (0.09%)    03-28 16:00
Open: 94.04
High: 94.48
Volume: 373,073
  
Pre. Close: 93.86
Low: 93.15
Market Cap: 12,933(M)
Technical analysis
2024-03-28 4:50:10 PM
Short term     
Mid term     
Targets 6-month :  110.79 1-year :  129.41
Resists First :  94.86 Second :  110.79
Pivot price 92.69
Supports First :  87.56 Second :  83.05
MAs MA(5) :  93.43 MA(20) :  92.08
MA(100) :  74.96 MA(250) :  71.94
MACD MACD :  3 Signal :  3.5
%K %D K(14,3) :  69.7 D(3) :  68.5
RSI RSI(14): 71.4
52-week High :  94.86 Low :  53.79
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ BRKR ] has closed below upper band by 16.3%. Bollinger Bands are 59.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 94.64 - 95.09 95.09 - 95.5
Low: 92.02 - 92.55 92.55 - 93.04
Close: 93.07 - 93.94 93.94 - 94.73
Company Description

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

Headline News

Thu, 28 Mar 2024
Bruker Co. (NASDAQ:BRKR) Given Average Rating of "Hold" by Analysts - MarketBeat

Thu, 28 Mar 2024
SG Americas Securities LLC Purchases 6647 Shares of Bruker Co. (NASDAQ:BRKR) - Defense World

Thu, 28 Mar 2024
Bruker Co. (NASDAQ:BRKR) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World

Wed, 27 Mar 2024
Bruker (BRKR) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Movies Canada

Fri, 22 Mar 2024
Bruker Corporation (BRKR) Hits 52-Week High: What's Driving It? - Yahoo Finance

Thu, 07 Mar 2024
Bruker Announces Closing of Chemspeed Technologies AG Acquisition - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 138 (M)
Shares Float 89 (M)
Held by Insiders 34.6 (%)
Held by Institutions 80.9 (%)
Shares Short 4,380 (K)
Shares Short P.Month 3,720 (K)
Stock Financials
EPS 2.9
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 9.48
Profit Margin 14.4 %
Operating Margin 16 %
Return on Assets (ttm) 7.6 %
Return on Equity (ttm) 33.6 %
Qtrly Rev. Growth 20.6 %
Gross Profit (p.s.) 0
Sales Per Share 21.5
EBITDA (p.s.) 4.35
Qtrly Earnings Growth 112.6 %
Operating Cash Flow 350 (M)
Levered Free Cash Flow 292 (M)
Stock Valuations
PE Ratio 32.39
PEG Ratio 2.4
Price to Book value 9.89
Price to Sales 4.36
Price to Cash Flow 36.94
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android